Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 13;3:932530. doi: 10.3389/fpain.2022.932530

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Kwilasz, Clements, Larson, Harris, Litwiler, Woodall, Todd, Schrama, Mitten, Maier, Van Dam, Rice and Watkins.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Myelin oligodendrocyte glycoprotein (MOG) induces lumbar spinal ventral funiculus demyelination. Sprague-Dawley (SD) from Experiment 2 received intradermal low-dose (0, 8, and 16 μg) myelin oligodendrocyte glycoprotein (MOG). Spinal cord tissue was collected on day 30 post-MOG administration and during 13 days of daily (+)-NTX administration. Only the 16-μg dose of MOG significantly decreased fluoromyelin staining intensity of ventral funiculus of lumbar spinal cord; however, this was not significantly reversed by (+)-NTX administration. Significant interaction between MOG and (+)-NTX treatment [F_(2,151) = 5.89; p < 0.01]. N = 5–8/group with 2–8 pictures analyzed per subject. Post-hocs: * indicates significant differences between groups (*p < 0.05).